Continuity & Shared Care After CAR-T
CAR-T care does not end at discharge. Patients return to their local care team for years of follow-up, and the handoff between the treating center and the referring practice is where continuity is won or lost.
CAR-T care does not end at discharge. Patients return to their local care team for years of follow-up, and the handoff between the treating center and the referring practice is where continuity is won or lost.
Follow-up lasts for years. FDA requires manufacturers to follow patients for 15 years after infusion, and European best-practice recommendations describe monitoring every three months through the first year and annually thereafter. Your job is to decide who owns each interval, where the visit happens, and how the results are provided back to the treating center.
There is no single way to divide CAR-T work for a community program. What matters is that the division is explicit. Shared care and outreach arrangements set out in service level agreements ensure responsibility for each stage of a patient's care is named rather than assumed.
One center performs apheresis and infusion; partners refer, work up and follow up.
Your center runs the whole pathway, from referral to long-term follow-up.
Service level agreements name who owns each stage and what each partner reports.
We’re here to help. Reach out today to connect with experts that can guide you.
